

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Daratumumab in combination for newly diagnosed systemic amyloid light-chain amyloidosis [ID3748]

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes, the company noted that people with amyloid light-chain amyloidosis with level IIIb cardiac status may face inequality in access, if excluded from NICE recommendation. This high-risk population was excluded from company's clinical trial programme because of their overall fitness levels and poor survival outcomes. These people are often excluded from other clinical trials and so evidence regarding this population is extremely rare.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

This is a theoretical equality issue which will depend on whether the committee decides to exclude this subgroup due to lack of information on risk-benefit of daratumumab in combination in this population. The committee will need to make this judgement in the light of the full available evidence. This equality issue will be considered in more detail by the committee.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Yes, consideration of subgroups based on the severity of heart failure has

Technology Appraisals: Scoping

Equality impact assessment for the proposed single technology appraisal daratumumab in combination for adults with newly diagnosed systemic amyloid light-chain amyloidosis [ID3748]

Issue date: April 2021

been added to the scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Henry Edwards

Date: 16/04/21